Antiviral Therapy in Patients after Treatment for Hepatitis C-Related Hepatocellular Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Despite great progress, antiviral treatment for chronic hepatitis C in patients with prior hepatocellular carcinoma (HCC) has been rarely investigated. We evaluated the effi cacy and safety of antiviral therapy following treatment for hepatitis C-related HCC. Methods: Thirteen patients (age 34 to 60 years) who were treated with peginterferon plus ribavirin after treatment for HCC were reviewed. Results: There were 6 patients with genotype 1 and 7 patients with genotype 2. All patients showed advanced fi brosis (≥F3) but belonged to the Child-Pugh class A. Treatment was stopped in 2 patients because of recurrent HCC and in 1 patient due to a lack of early virologic response. Seven patients achieved sustained virologic response and three patients relapsed. The sustained virologic response rate was 54%overall, 17% in genotype 1, and 86% in genotype 2. No signifi cant adverse events were reported. Conclusions: Antiviral therapy should not be excluded in patients who were previously treated with HCC with genotype 2 chronic hepatitis C, in which an effi cacious antiviral treatment for chronic hepatitis C was feasible. Additional study is needed to prove the validity of antiviral therapy in patients with genotype 1 hepatitis C-related HCC.
Abstract
Background/Aims: Despite great progress, antiviral treatment for chronic hepatitis C in patients with prior hepatocellular carcinoma (HCC) has been rarely investigated. We evaluated the effi cacy and safety of antiviral therapy following treatment for hepatitis C-related HCC. Methods: Thirteen patients (age 34 to 60 years) who were treated with peginterferon plus ribavirin after treatment for HCC were reviewed. Results: There were 6 patients with genotype 1 and 7 patients with genotype 2. All patients showed advanced fi brosis (≥F3) but belonged to the Child-Pugh class A. Treatment was stopped in 2 patients because of recurrent HCC and in 1 patient due to a lack of early virologic response. Seven patients achieved sustained virologic response and three patients relapsed. The sustained virologic response rate was 54%overall, 17% in genotype 1, and 86% in genotype 2. No signifi cant adverse events were reported. Conclusions: Antiviral therapy should not be excluded in patients who were previously treated with HCC with genotype 2 chronic hepatitis C, in which an effi cacious antiviral treatment for chronic hepatitis C was feasible. Additional study is needed to prove the validity of antiviral therapy in patients with genotype 1 hepatitis C-related HCC.
참고문헌 (29)
- Lauer GM, "Hepatitis C virus infection", N Engl J Med, 351, pp.41~52 (2001)
- Sinn DH, "Disease progression and the risk factor analysis for chronic hepatitis C", Liver Int, 28, pp.1363~1369 (2008)
- Formann E, "Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy", Aliment Pharmacol Ther, 23, pp.507~511 (2006)
- Yu ML, "A sustained virological response to interferon or interferon", ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan, 2006, pp.11, 985~994
- 윤현아, "만성 C형간염에서 페그인터페론과 리바비린 병합요법의 효과", Clinical and Molecular Hepatology, 14(1), pp.36~45 (2008), 대한간학회
- Manns MP, "Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Ueno S, "Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis", Hepatol Res, 24, pp.395~403 (2002)
- Liang TJ, "Pathogenesis of hepatitis C-associated hepatocellular carcinoma", Gastroenterology, 127(5 Suppl 1), pp.S62~S71 (2004)
- Hadziyannis SJ, "Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Fried MW, "Side effects of therapy of hepatitis C and their management", Hepatology, 36(5 Suppl 1), pp.S237~S244 (2002)
- Antonini MG, "Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin", Infection, 36, pp.250~255 (2008)
- McHutchison JG, "Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy", Am J Gastroenterol, 102, pp.880~889 (2007)
- Soza A, "Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C", Hepatology, 36, pp.1273~1279 (2002)
- Helbling B, "HCV-related advanced fibrosis", cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin, 2006, pp.13, 762~769
- Di Marco V, "Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial", J Hepatol, 47, pp.484~491 (2007)
- Hung CH, "Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatoce lular carcinoma in patients with hepatitis C virus-related cirrhosis", J Viral Hepat, 13, pp.409~414 (2006)
- Huang JF, "The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies: a multicenter prospective trial", J Hepatol, 54, pp.219~226 (2011)
- Sangfelt, "Apoptosis and cell growth inhibition as antitumor effector functions of interferons", Med Oncol, 18, pp.3~14 (2001)
- Stark GR, "How cells respond to interferons", Annu Rev Biochem, 67, pp.227~264 (1998)
- Yano H, "Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo", Liver Int, 26, pp.964~975 (2006)
- Damdinsuren B, "Interferon alpha receptors are important for antiproliferative effect of interferonalpha against human hepatocellular carcinoma cells", Hepatol Res, 37, pp.77~83 (2007)
- Nishiguchi S, "Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis", Lancet, 346, pp.1051~1055 (1995)
- Shiratori Y, "Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival", Ann Intern Med, 142, pp.105~114 (2005)
- Tanaka H, "Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients", Int J Cancer, 87, pp.741~749 (2000)
- Ikeda K, "Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer", Hepatology, 32, pp.228~232 (2000)
- Kubo S, "Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial", Ann Intern Med, 134, pp.963~967 (2001)
- Shiratori Y, "Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus", Ann Intern Med, 138, pp.299~306 (2003)
- Mazzaferro V, "Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis", Hepatology, 44, pp.1543~1554 (2006)